Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.
Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K. Makar AP, et al. Among authors: tummers p. Oncologist. 2016 Jun;21(6):745-54. doi: 10.1634/theoncologist.2015-0239. Epub 2016 Mar 23. Oncologist. 2016. PMID: 27009938 Free PMC article. Review.
Value of magnetic resonance and ¹⁸FDG PET-CT in predicting tumor response and resectability of primary locally advanced cervical cancer after treatment with intensity-modulated arc therapy: a prospective pathology-matched study.
Vandecasteele K, Delrue L, Lambert B, Makar A, Lambein K, Denys H, Tummers P, Van den Broecke R, Villeirs G, De Meerleer G. Vandecasteele K, et al. Among authors: tummers p. Int J Gynecol Cancer. 2012 May;22(4):630-7. doi: 10.1097/IGC.0b013e3182428925. Int J Gynecol Cancer. 2012. PMID: 22237382
Postoperative intensity-modulated arc therapy for cervical and endometrial cancer: a prospective report on toxicity.
Vandecasteele K, Tummers P, Makar A, van Eijkeren M, Delrue L, Denys H, Lambert B, Beerens AS, Van den Broecke R, Lambein K, Fonteyne V, De Meerleer G. Vandecasteele K, et al. Among authors: tummers p. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):408-14. doi: 10.1016/j.ijrobp.2011.12.020. Epub 2012 Feb 28. Int J Radiat Oncol Biol Phys. 2012. PMID: 22377596
Intensity-modulated arc therapy with cisplatin as neo-adjuvant treatment for primary irresectable cervical cancer. Toxicity, tumour response and outcome.
Vandecasteele K, Makar A, Van den Broecke R, Delrue L, Denys H, Lambein K, Lambert B, van Eijkeren M, Tummers P, De Meerleer G. Vandecasteele K, et al. Among authors: tummers p. Strahlenther Onkol. 2012 Jul;188(7):576-81. doi: 10.1007/s00066-012-0097-0. Epub 2012 Apr 19. Strahlenther Onkol. 2012. PMID: 22526231 Clinical Trial.
EXclusion of non-Involved uterus from the Target Volume (EXIT-trial): an individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques.
Vandecasteele K, Tummers P, Van Bockstal M, De Visschere P, Vercauteren T, De Gersem W, Denys H, Naert E, Makar A, De Neve W. Vandecasteele K, et al. Among authors: tummers p. BMC Cancer. 2018 Sep 17;18(1):898. doi: 10.1186/s12885-018-4800-0. BMC Cancer. 2018. PMID: 30223802 Free PMC article. Clinical Trial.
Neo-adjuvant treatment of adenocarcinoma and squamous cell carcinoma of the cervix results in significantly different pathological complete response rates.
Couvreur K, Naert E, De Jaeghere E, Tummers P, Makar A, De Visschere P, Van Bockstal M, Van Dorpe J, De Neve W, Denys H, Vandecasteele K. Couvreur K, et al. Among authors: tummers p. BMC Cancer. 2018 Nov 12;18(1):1101. doi: 10.1186/s12885-018-5007-0. BMC Cancer. 2018. PMID: 30419851 Free PMC article.
40 results